Keywords
BevacizumabAngiogenesisMedicineVascular endothelial growth factorCancer researchNeovascularizationMonoclonal antibodyImmunologyAntibodyChemotherapyInternal medicineVEGF receptors
Affiliated Institutions
Related Publications
Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model
Abstract Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related death worldwide. Liver resection or transplantation is curative for a subset o...
VEGF as a Therapeutic Target in Cancer
Tumors require nutrients and oxygen in order to grow, and new blood vessels, formed by the process of angiogenesis, provide these substrates. The key mediator of angiogenesis is...
Tumor angiogenesis: past, present and the near future
The concept of treating solid tumors by inhibiting tumor angiogenesis was first articulated almost 30 years ago. For the next 10 years it attracted little scientific interest. T...
Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis.
Vascular endothelial growth factor (VEGF) represents a growth factor with important pro-angiogenic activity, having a mitogenic and an anti-apoptotic effect on endothelial cells...
Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody
The hyperpermeability of tumor vessels to macromolecules, compared with normal vessels, is presumably due to vascular endothelial growth factor/vascular permeability factor (VEG...
Publication Info
- Year
- 2005
- Type
- review
- Volume
- 333
- Issue
- 2
- Pages
- 328-335
- Citations
- 956
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
956
OpenAlex
Cite This
Napoleone Ferrara,
Kenneth J. Hillan,
William Novotny
(2005).
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
Biochemical and Biophysical Research Communications
, 333
(2)
, 328-335.
https://doi.org/10.1016/j.bbrc.2005.05.132
Identifiers
- DOI
- 10.1016/j.bbrc.2005.05.132